Selegiline Oral — Membership Pricing

Other medications in Neurology

• Tetrabenazine
• Topiramate
• Valproic Acid
• Carbamazepine
• Deutetrabenazine
• Lamotrigine
• Levetiracetam
• Phenytoin

About Selegiline Oral

Selegiline oral is a medication primarily used to manage symptoms of Parkinson's disease, and in certain formulations, for depression. Understanding its role in your health and how to manage prescription costs is vital. TheDrugClub is dedicated to helping members save significantly on medications like selegiline, making essential treatments more accessible and affordable for everyone.

Selegiline oral is a prescription medication often prescribed to individuals living with Parkinson's disease. While primarily known for its role in Parkinson's, it's also used in other formulations (like the transdermal patch) for major depressive disorder. When prescribed orally, its main use is to help improve symptoms of Parkinson's disease, either alone in early stages or in combination with other medications like levodopa/carbidopa in more advanced stages.

How Selegiline Oral Works

Selegiline belongs to a class of drugs known as monoamine oxidase inhibitors (MAOIs). Specifically, at the doses typically prescribed for Parkinson's disease, it acts as a selective MAO-B inhibitor. Monoamine oxidase-B (MAO-B) is an enzyme in the brain responsible for breaking down dopamine, a neurotransmitter crucial for movement control. By inhibiting MAO-B, selegiline helps to increase and prolong the availability of dopamine in the brain, thereby reducing Parkinson's symptoms such as tremors, stiffness, and slow movement. At higher doses, selegiline can lose its selectivity and inhibit MAO-

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Selegiline Oral is approved for (FDA label)

Selegiline Hydrochloride Tablets USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of 'off' time, and patient self-rating of treatment success.

Source: Read the full FDA label on DailyMed. Label effective date: November 24, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Selegiline Oral (FDA label)

Introduction The number of patients who received selegiline in prospectively monitored pre-marketing studies is limited. While other sources of information about the use of selegiline are available (e.g., literature reports, foreign post-marketing reports, etc.) they do not provide the kind of information necessary to estimate the incidence of adverse events. Thus, overall incidence figures for adverse reactions associated with the use of selegiline cannot be provided. Many of the adverse reactions seen have also been reported as symptoms of dopamine excess. Moreover, the importance and severity of various reactions reported often cannot be ascertained. One index of relative importance, however, is whether or not a reaction caused treatment discontinuation.

Source: FDA prescribing information (DailyMed). Set ID: 040a97e5-efd1-4a2f-b737-2f13e5366d70. SPL document ID: 445cd6b2-2a0f-5f90-e063-6294a90ab877. Label effective date: November 24, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Selegiline Oral (FDA label)

Selegiline hydrochloride is contraindicated in patients with a known hypersensitivity to this drug. Selegiline is contraindicated for use with meperidine. This contraindication is often extended to other opioids. (See Drug Interactions .)

Source: FDA prescribing information (DailyMed). Set ID: 040a97e5-efd1-4a2f-b737-2f13e5366d70. SPL document ID: 445cd6b2-2a0f-5f90-e063-6294a90ab877. Label effective date: November 24, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Selegiline Oral (FDA label)

The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination (see CONTRAINDICATIONS ). Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and selegiline and selective serotonin reuptake inhibitors and selegiline. (See WARNINGS for details.) One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).

Source: FDA prescribing information (DailyMed). Set ID: 040a97e5-efd1-4a2f-b737-2f13e5366d70. SPL document ID: 445cd6b2-2a0f-5f90-e063-6294a90ab877. Label effective date: November 24, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.